Fentanyl pectin nasal spray in breakthrough cancer pain

Journal of Supportive Oncology

Volumn 8, Issue 4, 2010, Pages 184-190

  Taylor, Donald ^a   Galan, Vincent ^b   Weinstein, Sharon M ^c   Reyes, Evangeline ^d   Pupo Araya, Ana Rocio ^e   Rauck, Richard ^f  

^a Georgia Center for Cancer   (United States)

^b Southern Regional Health System   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Riverside CA ^*  (United States)

^e SEMECO   (United States)

^f Carolinas Pain Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT; PECTIN; PLACEBO;

ADULT; ANALGESIA; ARTICLE; BREAKTHROUGH CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; EPISTAXIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONCARDIAC CHEST PAIN; NOSE CONGESTION; NOSE OBSTRUCTION; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SWEATING; TASTE DISORDER; VOMITING;

ADMINISTRATION, INTRANASAL; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FENTANYL; HUMANS; MIDDLE AGED; NEOPLASMS; PAIN, INTRACTABLE; PATIENT ACCEPTANCE OF HEALTH CARE; PECTINS;

EID: 77956098539     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dahl JL. Pain: impediments and suggestions for solutions. J Natl Cancer Inst Monogr 2004;32:124-126. [15263053]
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281. [1697056]
3. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-839. [11857319]
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206. [15737812]
5. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-134. [10353500]
6. Portenoy RK, Bruns D, Shoemaker B, Shoemaker S. Breakthrough pain in community- dwelling patients with cancer pain and noncancer pain, 1: prevalence and characteristics. J Opioid Manag 2010;6:97-108. [20481174]
7. Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999;17:391-401.[10388244]
8. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 2001;15:9-18. [11212475]
9. Gomez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52. [12183094]
10. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64. [12507700]
11. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 2004;18:177-183.[15198130]
12. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44. [14622852]
13. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003;25:9-18. [12565184]
14. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92. [10989246]
15. Bennett DS, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain, 2: management. Pharm Ther 2005;30:354-361.
16. Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998;16:388-402. [9879164]
17. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-334. [17708123]
18. Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs 2010;70:57-72. [20030425]
19. Gordon SR, Berkey DB, Call RL. Dental need among hospice patients in Colorado: a pilot study. Gerodontics 1985;1:125-129. [3861444]
20. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 2001;22:820-825. [11576798]
21. Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 2005;30:496-497. [11576798]
22. Jacobsen R, Moldrup C, Christrup L. Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark. J Opioid Manag 2008;4:383-391. [19192766]
23. Jacobsen R, Moldrup C, Christrup L, et al. Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci 2009;23:190-208. [18785917]
24. Miaskowski C, Dodd MJ, West C, et al. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol 2001;19:4275-4279. [11731509]
25. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-770. [12139528]
26. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87:187-198. [12547019]
27. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009;6:543-552. [19413461]
28. Portenoy R, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (fpns) in the treatment of breakthrough cancer pain. Pain (in press).
29. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003;25:406-411. [12727037]
30. Breivik H, Cherny N, Collett B, et al. Cancerrelated pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-1433. [19244085]
31. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan- poloxamer 188. Int J Clin Pharmacol Ther 2010;48:138-145. [20137766]
32. Walker G, Wilcock A, Manderson C, et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003;17:219-221. [12701855]
33. Lemmens HJ, Wada DR, Munera C, et al. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials 2006;27:165-173. [16316789]
34. Straube S, Derry S, McQuay HJ, et al. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain: a systematic review. Br J Clin Pharmacol 2008;66:266-275. [18489611]